Sino Medical Sciences Technology (SHA:688108) obtained approval from a European Union regulator to reduce the regimen for its HT Supreme drug-eluting stent system, according to a Shanghai bourse filing on Thursday.
Under the approval, the stent may reduce the duration of dual antiplatelet medication to one month.
The medical device manufacturer's shares rose 1% at the close.